

ECONOMICAL ANALYSIS OF SUBCUTANEOUS VERSUS INTRAVENOUS TRASTUZUMAB



M. Camean-Castillo, C. Martinez-Diaz, J. GarciaDeParedes-Esteban, J. Diaz-Navarro, M. Gandara-LadronDeGuevara, M. Blanco-Castaño, E. Rios-Sanchez, S. Fenix-Caballero, C. Palomo-Palomo, J. Borrero-Rubio

Puerto Real University Hospital, Cádiz, Spain .

PURPOSE


To assess the cost minimization achieved by using

Subcutaneous trastuzumab (600mg/21 days)


Intravenous trastuzumab (various dosifications)

For treatment of HER2+ breast cancer

MATERIAL AND METHODS



RESULTS



CONCLUSION

1. Two-thirds of patients who received trastuzumab weighted more than 63kg.
2. Few patients of this group received subcutaneous trastuzumab.
3. Most of the patients of the study received a treatment with a higher cost than the new form subcutaneous trastuzumab.